News
PCRX
25.90
-3.39%
-0.91
Noteworthy Tuesday Option Activity: PCRX, CMG, CVNA
NASDAQ · 1d ago
Weekly Report: what happened at PCRX last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at PCRX last week (0408-0412)?
Weekly Report · 04/15 09:11
Pacira BioSciences (NASDAQ:PCRX) sheds US$55m, company earnings and investor returns have been trending downwards for past three years
Pacira BioSciences, Inc. (NASDAQ:PCRX) share price is down 60% over three years. The share price has fallen 33% in the last year, and is down 15% in a quarter. The company's earnings per share has dropped by 36% over the same period. The market may not be concerned about the drop in the share price, but is the company growing revenue? We look at whether there's a mismatch between the fundamentals and share price.
Simply Wall St · 04/11 12:39
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Pacira BioSciences is a provider of non-opioid pain management and regenerative health solutions. 6 analysts have shared their insights on Pacira Biosciences in the last three months. The company has an average price target of $49.0. The 12-month price targets assessed by analysts are lower than the previous average of $57.00.
Benzinga · 04/09 14:00
Pacira BioSciences Price Target Maintained With a $45.00/Share by Needham
Dow Jones · 04/09 10:26
Needham Reiterates Buy on Pacira BioSciences, Maintains $45 Price Target
Benzinga · 04/09 10:16
Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating
TipRanks · 04/09 10:16
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Pacira Pharmaceuticals (PCRX), Legend Biotech and Intellia Therapeutics (NTLA) have been recommended by 3 analysts with bullish sentiments. RBC Capital maintained a Buy rating on Pacira and Cantor Fitzgerald initiated coverage on the 3 Healthcare stocks. The analysts are bullish on the Healthcare sector as a whole.
TipRanks · 04/09 01:50
Weekly Report: what happened at PCRX last week (0401-0405)?
Weekly Report · 04/08 09:11
Commit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using Options
NASDAQ · 04/04 15:33
Weekly Report: what happened at PCRX last week (0325-0329)?
Weekly Report · 04/01 09:11
Weekly Report: what happened at PCRX last week (0318-0322)?
Weekly Report · 03/25 09:11
Weekly Report: what happened at PCRX last week (0311-0315)?
Weekly Report · 03/18 09:11
Analysts Expect IJR Will Reach $120
NASDAQ · 03/14 11:15
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis
Pacira BioSciences has won a key U.S. Food and Drug Administration designation for its gene-therapy product candidate for osteoarthritis of the knee. The FDA's first-ever RMAT designation for a product candidate in osteo arthritis. The company says the designation is supported by encouraging preliminary data.
Dow Jones · 03/13 11:41
Independent Director Of Pacira BioSciences Sold 85% Of Their Shares
Independent Director Gary Pace sold US$3.7m worth of Pacira BioSciences, Inc. Shares recently. The sale is the biggest single sale by an insider of the company in the last year. The insider sale amounts to 85% of the firm's share price. Pacira biosciences insiders didn't buy any shares over the last 12 months. The company has a high insider ownership of 1.2% of its shares. You can see the insider transactions at Pacira Biosecences   .
Simply Wall St · 03/11 10:47
Weekly Report: what happened at PCRX last week (0304-0308)?
Weekly Report · 03/11 09:11
Teva upgraded at J.P. Morgan on upcoming catalysts
J.P. Morgan reviewed its specialty pharma coverage and upgraded generic drugmaker Teva to Neutral from Underweight. Analyst cited a favorable catalyst set up in the months ahead for the company. Teva Pharmaceutical stock traded higher on Friday after the upgrade. J.p. Morgan on upcoming catalysts for Teva.
Seeking Alpha · 03/08 15:21
Pacira BioSciences Price Target Announced at $45.00/Share by JP Morgan
Dow Jones · 03/07 10:17
More
Webull provides a variety of real-time PCRX stock news. You can receive the latest news about Pacira Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.